Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T65054
(Former ID: TTDR00658)
|
|||||
Target Name |
Actin (ACT)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Vaginitis [ICD-11: GA02] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | RGN-259 | Drug Info | Phase 2 | Vaginal infection | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | RGN-259 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6. | |||||
REF 2 | Clinical pipeline report, company report or official report of Regulus Therapeutics. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.